Tanner Pharma Group is a global pharmaceutical services company, focused on implementing complex and innovative supply chains to enable access to medicines for patients around the world. Recently, we have also been involved in the distribution of medical devices for pandemic preparedness and response. We have distributed nearly 500 million Covid-19 lateral flow tests to the UKHSA, and we are now working with them to prepare for and mitigate future pandemics. As a pharmaceutical distributor, we represent a number of manufacturers with specialised products which have applications as medical countermeasures, and can manage the distribution, inventory management, and mobilisation of these products.
LEUKINE® (sargramostim) is a leukocyte growth factor which has several FDA-approved indications, including increasing survival after exposure to radiation events. There is strong evidence outlining its utility as an emergency medical countermeasure in response to a radiation event.
NUZYRA® (omadacycline) is a tetracycline-class antibacterial for the treatment of CABP and ABSSSI. However, it has also shown promise as a post-exposure prophylaxis after anthrax exposure and to treat lung infections caused by inhaling anthrax spores. The CDC have added Nuzyra as an alternative agent for the treatment, pre-exposure prophylaxis, and postexposure prophylaxis of primary bubonic and pharyngeal plague infections in adults.
